Table 2.
Gastric cancer cohort.
| Characteristics | Total (N = 170) | GCPM without ascites (N = 65) | GCPM with ascites (N = 105) | p |
|---|---|---|---|---|
| Sex, no. (%) | 0.525 | |||
| Male | 71 (41.8) | 17 (26.2) | 46 (43.8) | |
| Female | 99 (58.2) | 48 (73.8) | 59 (56.2) | |
| Median age (range), years | 60 (22–82) | 59 (27–81) | 60 (22–82) | 0.510 |
| Ethnicity, no. (%) | 0.019 | |||
| Caucasian | 95 (55.9) | 45 (69.2) | 50 (47.6) | |
| Asian | 74 (43.5) | 20 (30.8) | 54 (51.4) | |
| Others | 1 (0.6) | 0 (0) | 1 (1.0) | |
| BMI, median (range) | 22 (15–29) | 22 (16–29) | 22 (15–28) | 0.450 |
| Synchronous metastases, no. (%) | 0.019 | |||
| Yes | 142 (83.5) | 60 (92.3) | 82 (78.1) | |
| No | 28 (16.5) | 5 (7.3) | 23 (21.9) | |
| Diagnosis of GCPM, no. (%) | 0.031 | |||
| Positive peritoneal washing cytology | 6 (3.5) | 5 (7.7) | 1 (0.1) | |
| Macroscopic PM | 164 (96.5) | 60 (92.3) | 104 (99.9) | |
| Type of IP-directed chemo, no. (%) | 0.011 | |||
| PIPAC | 96 (56.5) | 45 (69.2) | 51 (48.6) | |
| Catheter-based IPC | 74 (43.5) | 20 (30.8) | 54 (51.4) | |
| Median cycles of IP-directed treatment (range) | 3 (0–36) | 2 (1–19) | 3 (0–36) | 0.053 |
| Median PCI (interquartile range) | 18 (9–28) | 9 (4–14) | 23 (16–33) | <0.001 |
Patient and disease characteristics overall and according to two subgroups of patients: GCPM without ascites and GCPM with ascites.
BMI, body mass index; GCPM, gastric cancer and peritoneal metastasis; IP, intra-peritoneal; IPC, intraperitoneal chemotherapy; PCI, peritoneal cancer index; PIPAC, pressurized intraperitoneal aerosolized chemotherapy; PM, peritoneal metastasis.